Biomonitor Acquires the Irish Theranostic Company Neutekbio
News Dec 05, 2008
Biomonitor A/S has completed the acquisition of the Irish company Neutekbio Ltd. on 27 November 2008. Neutekbio's technologies and products complement Biomonitor’s current offerings to physicians and clinics involved in treatment of patients with Multiple Sclerosis, Rheumatoid Arthritis and Crohn’s disease worldwide.
Biomonitor will continue the R&D and manufacturing operations in Ireland and the ongoing collaboration with the French research institution CNRS in Paris. CNRS is a leading research organization in cell biology, virology, and medicine.
The acquisition is made possible by the financial support from Sunstone Capital in Denmark. "We are committed to supporting Biomonitor in becoming a leader in monitoring and improving costly protein based therapies - also by acquisition of supplementary products and technologies when possible", says Soren Lemonius, Chairman of Biomonitor and Partner in Sunstone Capital.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Synthetic Biology Breakthrough Means Bacteria Could Produce Our Essential DrugsNews
Bacteria could be programmed to efficiently produce drugs, thanks to breakthrough research into synthetic biology using engineering principles.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018